Search - tctmd.com

Displaying 881 - 900 of 1123

Sort: Relevancy | Date

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Presentation

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

April 18, 2017

News Daily News

Physically Active Less Likely to Die After MI Than Sedentary Individuals

Michael O'Riordan

April 14, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

Presentation

Early Invasive vs Selective Strategy for NSTE ACS

April 11, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

Presentation Fellows 2017

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Manish A. Parikh, David J. Cohen

April 07, 2017

Presentation Fellows 2017

Antiplatelet Therapy for the Interventionalist

Presenter: Manish A. Parikh, Gregg W. Stone

April 07, 2017

News Daily News

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

Todd Neale

March 28, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

Presentation ACC 2017

The RAD-MATRIX Study

Presenter: Alessandro Sciahbasi

March 19, 2017

News Conference News ACC 2017

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Advertisement

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

Physically Active Less Likely to Die After MI Than Sedentary Individuals

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Early Invasive vs Selective Strategy for NSTE ACS

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Antiplatelet Therapy for the Interventionalist

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

The RAD-MATRIX Study

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content